Global Arbidol Tablets (COVID-19) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Arbidol Tablets (COVID-19) Market Research Report 2024
Arbidol Hydrochloride as known as Arbidol, is an antiviral treatment for influenza infection.
According to Mr Accuracy reports’s new survey, global Arbidol Tablets (COVID-19) market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Arbidol Tablets (COVID-19) market research.
In February 2020, Li Lanjuan, an expert of the National Health Commission of China, proposed using Arbidol (umifenovir) together with darunavir as a potential treatment during the 2019–20 coronavirus outbreak. Chinese experts claim that preliminary tests had shown that arbidol and darunavir could inhibit replication of the virus. However, later studies showed that it did not show any efficacy in treating the Covid-19 disease. However usage by itself as a post-exposure prophylaxis (PEP) of Covid-19 transmission has been demonstrating positive results though further research is still warranted.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Arbidol Tablets (COVID-19) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
JSC Pharmstandard
Jiangsu Wuzhong Pharmaceutical
CSPC Ouyi Pharmaceutical
Simcere Pharmaceutical
Segment by Type
50mg
100mg
Anti Influenza Virus
COVID-19
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Arbidol Tablets (COVID-19) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Arbidol Tablets (COVID-19) market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Arbidol Tablets (COVID-19) market research.
In February 2020, Li Lanjuan, an expert of the National Health Commission of China, proposed using Arbidol (umifenovir) together with darunavir as a potential treatment during the 2019–20 coronavirus outbreak. Chinese experts claim that preliminary tests had shown that arbidol and darunavir could inhibit replication of the virus. However, later studies showed that it did not show any efficacy in treating the Covid-19 disease. However usage by itself as a post-exposure prophylaxis (PEP) of Covid-19 transmission has been demonstrating positive results though further research is still warranted.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Arbidol Tablets (COVID-19) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
JSC Pharmstandard
Jiangsu Wuzhong Pharmaceutical
CSPC Ouyi Pharmaceutical
Simcere Pharmaceutical
Segment by Type
50mg
100mg
Segment by Application
Anti Influenza Virus
COVID-19
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Arbidol Tablets (COVID-19) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices